Table 1

Baseline characteristics in the vitamin D and placebo study arms (N = 259)
Baseline characteristic Randomization
Drug intervention (n = 132) Placebo intervention (n = 127)
Age (years), Mean ± SD 27.8 ± 13.2 28.3 ± 14.1
Gender, Men 71 (53.8) 70 (55.1)
Weight (kg), Mean ± SD 45.2 ± 7.6 45.6 ± 9.0
BMI, Mean (range) 17.2 (11–25) 17.3 (11–27)
MUAC (cm), (range) 21.2 (14–30) 21.1 (15–32)
Disease Symptom(s)present
 Cough 127 (96.2) 125 (98.4)
 Haemoptysis 30 (22.7) 34 (26.8)
 Dyspnoea 84 (63.6) 85 (66.9)
 Chest pain 84 (63.6) 84 (66.1)
 Night sweats 69 (52.3) 55 (43.3)
 Pale conjunctiva 70 (53) 67 (52.8)
 Tachycardia 87 (65.9) 86 (67.7)
 Fever 49 (37.1) 68 (53.5)
 Crepitations 50 (37.9) 38 (29.9)
 Rhonchi 19 (14.4) 21 (16.5)
 Reduced breath sounds 26 (19.7) 20 (15.7)
TB score, Mean ± SD, 95 CI 6.68 ± 2.04, 6.3-7.03 6.85 ± 2.50, 6.4-7.29
Distribution by Severity Class/TB score*
 Class I/0 – 5 32 (24.2) 40 (31.5)
 Class II/6 – 7 51 (38.6) 41 (32.3)
 Class III/≥ 8 49 (37.1) 46 (36.2)
Serum-25-(OH)D3 levels; Mean, (SD) 20.58 ± 8.51 22.87 ± 10.33
25(OH)D3 >30 ng/ml (Optimal) 18 (13.6) 25 (19.7)
25(OH)D3 20-30 ng/ml (Insufficient) 46 (34.8) 54 (42.5)
25(OH)D3 < 20 ng/ml (Deficient) 70 (53) 51(41)
Chest X-Ray Classification1
 Minimally Advanced disease 10 (7.6) 13 (10.2)
 Moderately Advanced disease 77 (58.3) 62 (48.8)
 Far Advanced disease 45 (34.1) 52 (40.9)
 No Cavity 7 (5.3) 4 (3.1)
 Cavity size < 4 cm 60 (45.5) 59 (46.5)
 Cavity size ≥ 4 cm 65 (49.2) 64 (50.4)
 No. of zones involved 3, Mean ± SD 3.61 ± 1.40 3.64 ± 1.48
Sputum microbial load (microscopy)2
Scant, 1–9 AFB/100 fields 4 (3.0) 2 (1.6)
 +1, 10–99 AFB/100 fields, 36 (27.3) 34 (26.8)
 +2, 1–10 AFB/50 fields, 25 (18.9) 23 (18.1)
 +3, >10 AFB/20 fields, 67 (50.8) 68 (53.5)
IFN-g levels (pg/ml) mean ± SD
Unstimulated levels 0.2 ± 2.6 0 ±0
ESAT6-stimulated 413 ±977 303 ±804
MTBs-stimulated 2826 ±1391 2858 ±1337

MUAC Mid Upper Arm Circumference; BMI Body Mass Index; s-25-(OH)D3 = serum 25- hydroxyvitamin D3.* Severity Class (TB score) [10];1Chest X ray classification: Each hemi-lung was divided into 3 zones (total 6 lung zones): active parenchymal and cavitary disease, exclusive of old fibrotic scarring, recorded as ‘zone involvement’ [11,12]. 2Diagnostic Standards and Classification of Tuberculosis, National Tuberculosis Association of the USA, 1961. Data are presented here as number (%), unless stated otherwise.

Salahuddin et al.

Salahuddin et al. BMC Infectious Diseases 2013 13:22   doi:10.1186/1471-2334-13-22

Open Data